Revisiting: GLP-1 receptor distribution: central and peripheral — setting out what I have, and where I think it stops being reliable.
An honest uncertainty about GLP-1 receptor distribution rather than a disguised assertion.
I do not know the answer and I have not been able to find one. What I have is the shape of the question, which may be worth more than my guess at the answer.
That reframing is the whole thing. The facts I already had.
Narrowing post #8, because the general version has more than one answer.
Species differences in receptor pharmacology are substantial in this family, which is one reason rodent data has translated unevenly.
Long-term receptor changes: very little is known about what happens to receptor expression, signalling, and downstream effects over years of exposure to these compounds. That is exactly the knowledge gap phase 3 trials exist to fill.
I have no interest in any supplier named above.
Central versus peripheral action: GLP-1 agonism works through both central nervous system effects (appetite) and peripheral effects (gastric motility, insulin). The balance is not fully characterised.
It cost nothing to check and would have cost something not to.
Long-term receptor changes: very little is known about what happens to receptor expression, signalling, and downstream effects over years of exposure to these compounds. That is exactly the knowledge gap phase 3 trials exist to fill.
This is where my knowledge stops and I would rather mark the edge than blur it.
Taking post #53 at face value and following it one step further.
Pharmacological class effects: all GLP-1 agonists slow gastric emptying and suppress appetite. Those are class effects, not unique to one compound. Effects that differ between compounds are usually about potency or receptor selectivity.
Worth saying I have only my own numbers here, and n is small.
Useful. I had the fact and not the reason, which turns out to be the important half.
Read the full topic (67 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Amylin receptor signalling and satiety
Amylin receptor signalling and satiety Writing it up because I had to work it out twice and would rather nobody else did. Asking about amylin receptor signalling and satiety directly, because I have read four…
|
+22 | 26 | 1.8k | 9mo |
|
GLP-1 receptor distribution: central and peripheral
Posting this under the heading it deserves: GLP-1 receptor distribution: central and peripheral Everything below is what sits behind that. I have spent a fortnight trying to pin GLP-1 receptor distribution…
|
+90 | 98 | 30k | 22h |
|
Follow-up: Glucagon receptor agonism in a weight-loss compound
Glucagon receptor agonism in a weight-loss compound Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about Glucagon receptor agonism that I did not know…
|
+5 | 9 | 21k | 7mo |
|
Why appetite effects are mostly central
Why appetite effects are mostly central I have a specific reason for asking rather than idle curiosity, and the context is below. Appetite effects: what I expected, what I found, and the gap between them. I…
|
2 | 56k | 16mo | |
|
GIP receptor agonism and the argument about direction
GIP receptor agonism and the argument about direction — setting out what I have, and where I think it stops being reliable. A question about GIP receptor agonism that I think has a definite answer, unlike…
|
2 | 867 | 10mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Amylin receptor signalling and satiety
Amylin receptor signalling and satiety Writing it up because I had to work it out twice and would rather nobody else did. Asking about amylin receptor signalling and satiety directly, because I have read four…
|
+22 | 26 | 1.8k | 9mo |
|
Historical amylin analogues and what happened to them
Posting this under the heading it deserves: Historical amylin analogues and what happened to them Everything below is what sits behind that. Proposing that historical amylin analogues deserves a maintained…
|
+29 | 36 | 31k | 1d |
|
What is genuinely unknown about long-term amylin agonism
What is genuinely unknown about long-term amylin agonism — that is the question, and I have not found it answered plainly anywhere I have looked. A comparison question rather than a question about one…
|
+83 | 91 | 46k | 1d |
|
Why retatrutide discussion here is more cautious than elsewhere
Why retatrutide discussion here is more cautious than elsewhere I have a specific reason for asking rather than idle curiosity, and the context is below. A question about retatrutide discussion that I think…
|
+7 | 12 | 7.7k | 2mo |
|
Triple agonism: additive, synergistic, or neither?
The question in the title: Triple agonism: additive, synergistic, or neither? I will give what I have already checked below so nobody repeats it. Asking about triple agonism on behalf of the question I keep…
|
+71 | 80 | 38k | 11mo |